AbCellera Biologics initiated at buy at Truist on antibody tech platform

Nov. 16, 2022 10:38 AM ETAbCellera Biologics Inc. (ABCL)By: Jonathan Block, SA News Editor6 Comments

Wall Street sign, New York City, USA


  • Truist has initiated AbCellera Biologics (NASDAQ:ABCL) with a buy citing the company's platform that allows for the rapid discovery of antibodies.
  • The firm has a price target of $29 per share (100% upside based on Tuesday's close).
  • Analyst

Recommended For You

Comments (6)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.